The primary mission of the University of Rochester (UR) Developmental Center For AIDS Research (D-CFAR) is to raise the overall quality and quantity of HIV/AIDS research at the UR. This objective will be achieved by the establishment of four interconnected core facilities, and by leveraging the infrastructure created for the UR's Clinical and Translational Science Institute (CTSI). The Administrative Core (Core A) will oversee the progress of the entire D-CFAR and facilitate functions necessary for the day-to-day function of the D-CFAR through organizational and fiscal oversight, support of program communications and program evaluation, and creation of a Bioinformatics resource that will support the entire D-CFAR program. The Developmental Core (Core B) will catalyze new multidisciplinary research on HIV/AIDS by funding pilot awards that support new collaborative efforts in strategically selected """"""""areas of opportunity"""""""". Support will also be provided for Traveling Fellowships and Mentored Investigator Awards patterned on the K08 mechanism;this will complemented by the creation of a structured mentoring program for young faculty and a grant facilitation service. New scientific seminar programs will also be supported, as well as pilot collaborations with international partners in South Africa. The Clinical Science Core (Core C) will be structured around the concept of a """"""""Protocol Team Service"""""""", that draws on the 20-year experience of the major UR HIV/AIDS clinical research programs. This will provide an 'investigator-centered'service that addresses the most pressing needs that clinical researchers face as they design, implement and conduct their studies, including support for Biostatistics, Data Management and Biomathematical Modeling. Core C will also support research collaborations with partners in South Africa. Finally, the Basic Research Core (Core D) will provide a full range of virology and immunology assays, as well as access to institutional core facilities. New services will include the creation of a Recombinant Protein Expression service, in response to faculty needs that were identified during the strategic planning process. Additional services will be provided through Molecular Virology and Flow Cytometry services, and will include availability of lentiviral vectors;a centralized Sample Repository will be also created, to facilitate access to, and storage of, clinical specimens. The success of the D-CFAR mission will be ensured by oversight from Internal and External Advisory Boards, a formal outcomes assessment program, and an active, effective strategic planning process.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI078498-03
Application #
7844939
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Program Officer
Namkung, Ann S
Project Start
2008-05-01
Project End
2013-04-30
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
3
Fiscal Year
2010
Total Cost
$742,313
Indirect Cost
Name
University of Rochester
Department
Microbiology/Immun/Virology
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Ocque, Andrew J; Hagler, Colleen E; Morse, Gene D et al. (2018) Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid. J Pharm Biomed Anal 156:163-169
McMillan, JoEllyn; Szlachetka, Adam; Slack, Lara et al. (2018) Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrob Agents Chemother 62:
Piekna-Przybylska, Dorota; Nagumotu, Kavyasri; Reid, Danielle M et al. (2018) HIV-1 infection renders brain vascular pericytes susceptible to the extracellular glutamate. J Neurovirol :
Braksmajer, Amy; Simmons, Janie; Aidala, Angela et al. (2018) Effects of Discrimination on HIV-Related Symptoms in Heterosexual Men of Color. Am J Mens Health 12:1855-1863
Loelius, Shannon G; Lannan, Katie L; Blumberg, Neil et al. (2018) The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro. Thromb Res 169:96-104
Loelius, Shannon G; Spinelli, Sherry L; Lannan, Katie L et al. (2018) In Vitro Methods to Characterize the Effects of Tobacco and Nontobacco Products on Human Platelet Function. Curr Protoc Toxicol 76:e46
Rice, John D; Strawderman, Robert L; Johnson, Brent A (2018) Regularity of a renewal process estimated from binary data. Biometrics 74:566-574
Nogales, Aitor; Piepenbrink, Michael S; Wang, Jiong et al. (2018) A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody. Sci Rep 8:4374
Zhou, Tian; Su, Hang; Dash, Prasanta et al. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151:53-65
Horita, Yasuhiro; Alsultan, Abdullah; Kwara, Awewura et al. (2018) Evaluation of the Adequacy of WHO Revised Dosages of the First-Line Antituberculosis Drugs in Children with Tuberculosis Using Population Pharmacokinetic Modeling and Simulations. Antimicrob Agents Chemother 62:

Showing the most recent 10 out of 192 publications